Abstract
Oral tongue squamous cell carcinoma (OTSCC) have an increasing incidence in young patients and many have an aggressive course of disease. The molecular mechanisms for this increase are unknown and biologic markers to identify high risk patients are lacking.
In an unbiased data screening for differential protein expression of younger (≤45 years) and older (>45 years) OTSCC patients in The Cancer Genome Atlas (TCGA) cohort (n=98) we identified Protein kinase C alpha (PRKCA), to be significantly more frequently overexpressed in younger versus older patients (p=0.0001). These results were experimentally validated and confirmed in an independent Austrian OTSCC patient sample (n=34) by immunohistochemistry (p=0.0026). PRKCA upregulation was associated with negative anamnesis for alcohol consumption (p=0.009) and tobacco smoking (p=0.02). Univariate and multivariate analysis of overall survival (OS) and disease-free survival (DFS) showed a significantly worse prognosis in patients with tumors overexpressing PRKCA regarding OS (univariate p= 0.04, multivariate p< 0.01). In the young subgroup both OS and DFS were significantly decreased in PRKCA positive patients (both p< 0.001). TCGA messenger RNA enrichment analysis showed 24 mRNAs with significant differential expression in PRKCA positive OTSCC (all p≤ 0.05 after Benjamini-Hochberg correction).
Our findings suggest the potential existence of a distinct molecular subtype of alcohol and tobacco negative, high risk OTSCC in a significant proportion of early onset individuals. Our findings warrant validation in additional OTSCC patient cohorts. Further analysis of the molecular PRKCA interactome may decipher the underlying mechanisms of carcinogenesis and clinicopathological behavior of PRKCA overexpressing OTSCC.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
The study was not registered to a trial registry because of its observational, restrospective design
Funding Statement
Funding was provided by internal grants of the Medical University of Vienna. This research did not receive any specific grant from third-party agencies in the public, commercial, or not-for-profit sector.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of the Medical University of Vienna, Austria Approval no. 1262/2019
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Statement: Conflict of interest: None declared
Funding: Funding was provided by internal grants of the Medical University of Vienna. This research did not receive any specific grant from third-party agencies in the public, commercial, or not-for-profit sector.
Data Availability
All relevant data regarding the Viennese study sample are included in the manuscript. Protein expression data extracted from the TCGA databank and adapted for the analysis in this study have been submitted as supplementary material. All relevant genomic and transcriptomic datasets analysed in this study are freely available for download under the public URLs provided below.
Abbreviations
- OTSCC
- oral tongue squamous cell carcinoma
- TCGA
- The Cancer Genome Atlas
- PRKCA
- protein kinase C alpha
- OS
- overall survival
- ANXA1
- Annexin 1
- DFS
- disease-free survival
- HNSCC
- head and neck squamous cell carcinoma
- HPV
- human papilloma virus
- CNV
- copy number variant
- LADC
- lung adeno carcinoma
- AJCC
- American Joint Committee on Cancer
- RPPA
- reverse phase protein array
- WMA
- World Medical Association
- IHC
- immunohistochemistry
- EMT
- epithelial-to-mesenchymal transition
